Diese Webseite nutzt Cookies zur Verbesserung des Erlebnisses unserer Besucher. Indem Sie weiterhin auf dieser Webseite navigieren, erklären Sie sich mit unserer Verwendung von Cookies einverstanden.
ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
ITM Acquires a New Platform for the Development of Next-Generation Theranostics
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
Julia Hofmann
Head of Corporate Communications
Phone: +49 89 329 8986 1500